18 Atopic Dermatitis Clinical Trials in Cincinnati, OH (2026)

Q: How do I join a clinical trial in Cincinnati?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you.

Recruiting Atopic Dermatitis Studies in Cincinnati

NCT06859762Recruiting

A First-in-Human Study of YL217 in Patients With Advanced Solid Tumors

A Phase 1 First-in-Human study of YL217 in Patients with Advanced Solid Tumors...

Cincinnati, OHPHASE1630 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT07419295Recruiting

A Clinical Trial of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) to Treat Urothelial Cancer (MK-2870-031)

Researchers are looking for new ways to treat locally advanced or metastatic urothelial cancer (UC). Current treatments for locally advanced or metastatic UC include chemotherapy, immunotherapy, and t...

Cincinnati, OHPHASE3590 participantsMerck Sharp & Dohme LLC

View Study Details

NCT06384352Recruiting

Safety,Tolerability, Pharmacokinetics, and Efficacy of YL211 in Patients With Advanced Solid Tumors

This is a multicenter, open-label, Phase 1 study. The study will enroll subjects with advanced solid tumors. It consists of six parts. Objectives for Dose-Escalation Parts (Part 1 and Part 4) To evalu...

Cincinnati, OHPHASE1500 participantsMediLink Therapeutics (Suzhou) Co., Ltd.

View Study Details

NCT05916339Recruiting

AWARE: Management of ADHD in Autism Spectrum Disorder

This study is a pragmatic clinical trial examining the comparative effectiveness of two stimulant medications (methylphenidate and amphetamine) in the treatment of ADHD in children and adolescents wit...

Cincinnati, OHPHASE4500 participantsDaniel Coury

View Study Details

NCT05889624Recruiting

Responding With Evidence and Access for Childhood Headaches

This comparative effectiveness study will clarify current first-line preventive treatment approaches for use by neurologists, psychologists, and primary care providers in the context of real world car...

Cincinnati, OHNA400 participantsChildren's Hospital Medical Center, Cincinnati

View Study Details

NCT06241456Recruiting

FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

This is a phase 1 study designed to evaluate the safety, tolerability, and antitumor activity of FT825 (also known as ONO-8250) with or without monoclonal antibody therapy following chemotherapy in pa...

Cincinnati, OHPHASE1351 participantsFate Therapeutics

View Study Details

NCT05839379Recruiting

Targeted Pediatric High-Grade Glioma Therapy

The goal of this study is to perform genetic sequencing on brain tumors from children, adolescents, and young adult patients who have been newly diagnosed with a high-grade glioma. This molecular prof...

Cincinnati, OH350 participantsNationwide Children's Hospital

View Study Details

NCT06234397Recruiting

Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors

This is a First-in-Human, Phase 1, Dose-Escalation and Dose-Expansion study of BH3120, as a single agent and in combination with pembrolizumab, to assess safety, tolerability, MTD, RP2D, PK, and effic...

Cincinnati, OHPHASE1216 participantsHanmi Pharmaceutical Company Limited

View Study Details

NCT04421248Recruiting

Biomarker Validation in Motor System Physiology in Attention Deficit Hyperactivity Disorder

Attention-Deficit/Hyperactivity Disorder (ADHD) is the most commonly diagnosed neurobehavioral disorder in childhood. Children with ADHD struggle in school due to problems with attention and high leve...

Cincinnati, OHPHASE4214 participantsDonald Gilbert, MD, MS, FAAN, FAAP

View Study Details

NCT06971614Recruiting

A Study of T3011 in Patients With BCG-Unresponsive NMIBC or BCG-Exposed, Chemotherapy-Unresponsive NMIBC

This is a Phase II clinical study to evaluate the efficacy and safety of intravesical T3011 injection in participants with BCG-unresponsive high-risk NMIBC or BCG-exposed, chemotherapy-unresponsive in...

Cincinnati, OHPHASE2160 participantsImmVira Pharma Co. Ltd

View Study Details

NCT06425926Recruiting

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors

GIM-531 is a first-in-class, orally bioavailable small molecule that is being developed for the treatment of advanced solid tumors as a single agent and rescue therapy. GIM-531 exhibits its primary ef...

Cincinnati, OHPHASE1117 participantsGeorgiamune Inc

View Study Details

NCT06504160Recruiting

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

This is a Phase 1b, randomized, placebo/vehicle-controlled, double-blinded, multi-center trial. It is designed to assess the safety and efficacy of S. hominis A9 (ShA9) topical application as a treatm...

Cincinnati, OHPHASE186 participantsNational Institute of Allergy and Infectious Diseases (NIAID)

View Study Details

NCT05038150Recruiting

Study of SGN1 in Patients With Advanced Solid Tumor

Objectives:To assess the safety and tolerability followed by a dose expansion study to characterize safety, and preliminary efficacy of SGN1 in participants with refractory solid tumors. Study Ration...

Cincinnati, OHPHASE170 participantsGuangzhou Sinogen Pharmaceutical Co., Ltd

View Study Details

NCT06096974Recruiting

Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS

This study will evaluate the safety, tolerability, drug levels, pharmacodynamic effects, and clinical activity of YL 17231 in patients with advanced solid tumors harboring mutations in KRAS, HRAS, or ...

Cincinnati, OHPHASE160 participantsShanghai YingLi Pharmaceutical Co. Ltd.

View Study Details

NCT06161974Recruiting

Study of Olutasidenib and Temozolomide in HGG

The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation...

Cincinnati, OHPHASE260 participantsRigel Pharmaceuticals

View Study Details

NCT06187402Recruiting

A Study of LM-24C5 For Advanced Solid Tumors

To assess the safety and tolerability, obtain the recommended phase 2 dose (RP2D)/optimal biologic dose (OBD) and/or Maximum Tolerated Dose (MTD) for LM-24C5 in subjects with advanced solid tumors....

Cincinnati, OHPHASE149 participantsLaNova Medicines Limited

View Study Details

NCT07225036Recruiting

Promoting Immunotherapy Efficacy With Low-Dose Liver RT

The purpose of this study is to see if adding Low-Dose Liver Radiation (LD-LRT) improves progression free survival (PFS). This study is for patients with either melanoma or non-small cell lung cancer ...

Cincinnati, OHNA21 participantsJordan Kharofa

View Study Details

NCT06333899Recruiting

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1. It will also evaluate the s...

Cincinnati, OHEARLY_PHASE115 participantsNationwide Children's Hospital

View Study Details

About Atopic Dermatitis Clinical Trials in Cincinnati

Atopic dermatitis (eczema) is a chronic inflammatory skin condition causing itchy, red, and dry skin. It is the most common form of eczema, often beginning in childhood. Treatment includes moisturizers, topical corticosteroids, immunomodulators, and newer biologics like dupilumab.

There are currently 18 atopic dermatitis clinical trials recruiting participants in Cincinnati, OH. These studies are seeking a combined 4,389 participants. Research is being sponsored by MediLink Therapeutics (Suzhou) Co., Ltd., Merck Sharp & Dohme LLC, Daniel Coury and 13 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Atopic Dermatitis Clinical Trials in Cincinnati — FAQ

Are there atopic dermatitis clinical trials in Cincinnati?

Yes, there are 18 atopic dermatitis clinical trials currently recruiting in Cincinnati, OH. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Cincinnati?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Cincinnati research site will contact you about next steps.

Are clinical trials in Cincinnati free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Cincinnati studies also compensate for your time and travel.

What atopic dermatitis treatments are being tested?

The 18 active trials in Cincinnati are testing new therapies including novel drugs, biologics, and treatment approaches for atopic dermatitis.

Data updated October 15, 2026 from ClinicalTrials.gov